In a study by Garg et al., whole-exome sequencing was performed on 13 matched samples at diagnosis, relapse, and remission, followed by targeted sequencing of 299 genes in 67 AML patients with FLT3-ITD mutations, identifying an unexpectedly high FAT1 mutation rate of up to 10% (8/80). This evidence concerns the gene FLT3 and acute myeloid leukemia.